Analyst Price Target News: Eli Lilly, Dave & Buster’s (September 16th, 2025)
By: Matthew Otto
Eli Lilly’s Orforglipron Pill May Get Accelerated FDA Review
Eli Lilly’s experimental oral weight-loss drug, orforglipron, may qualify for the U.S. Food and Drug Administration’s (FDA) new “Commissioner’s National Priority Voucher” program, which could shorten the review timeline to one or two months compared with the agency’s standard 10-month process.
The program, launched in July 2025, will issue up to five vouchers in its first year for drugs that meet criteria such as addressing public health crises, lowering costs, or onshoring drug manufacturing. Analysts have noted that Lilly’s candidate could be a strong fit, given the rising U.S. obesity rate—currently about 42% of adults, or roughly 110 million people. Globally, more than 1 billion people are estimated to be living with obesity, according to World Health Organization data. Novo Nordisk’s competing oral GLP-1 therapy is also under FDA review, with a decision expected in the fourth quarter of 2025.
Clinical trial data released earlier this year showed patients taking orforglipron lost an average of 12.4% of body weight. In the U.S., obesity contributes to more than 300,000 premature deaths annually and costs the healthcare system an estimated $173 billion a year. Lilly’s injectable tirzepatide—sold under Mounjaro and Zepbound—carries an estimated net price of $8,000 annually, or about $664 per month, while out-of-pocket purchase options run $499 a month.
JP Morgan Lowers Eli Lilly Price Target by 4.5% While Maintaining Rating
- JP Morgan analyst Chris Schott kept an Overweight rating but lowered the price target from $1100 to $1050.
Which Analyst has the best track record to show on LLY?
Analyst Seamus Fernandez (GUGGENHEIM) currently has the highest performing score on LLY with 16/21 (76.19%) price target fulfillment ratio. His price targets carry an average of $214.51 (32.48%) potential upside. Eli Lilly stock price reaches these price targets on average within 539 days.
Dave & Buster’s Q2 2025 Results Show Lower Earnings and Flat Revenue Against Estimates
Dave & Buster’s Entertainment reported second-quarter fiscal 2025 revenue of $557.4 million, nearly unchanged from $557.1 million in the prior year and below the consensus estimate of $565 million. Comparable store sales fell 3% year-over-year.
Net income was $11.4 million, or $0.32 per diluted share, compared with $40.3 million, or $0.99 per share, in the same period last year. On an adjusted basis, earnings were $0.4 per share, falling short of analyst expectations of $0.95 by $0.55.
Operating income declined to $53 million from $84.5 million, while store operating income before depreciation and amortization decreased to $155.4 million from $173.5 million. Operating cash flow totaled $34 million, down from $101.8 million a year earlier, with quarter-end liquidity at $443.3 million.
The company opened three new domestic Dave & Buster’s stores during the quarter, bringing its total to 237 company-owned stores compared with 224 in the prior year. Following the quarter’s close, it added one more Dave & Buster’s and two Main Event locations. International expansion continued with a second franchise location opened in India, with at least five more planned over the next six months.
Dave & Buster’s also completed three store remodels and realized about $77 million from sale-leaseback and real estate financing transactions. Long-term debt stood at $1.55 billion, up from $1.48 billion earlier in the year, with a net total leverage ratio of 3.2x.
UBS Maintains Neutral on Dave & Buster’s, Cuts Price Target by 13.8%
- UBS analyst Dennis Geiger maintained a Neutral rating but lowered the price target from $29 to $25.
Which Analyst has the best track record to show on PLAY?
Analyst Dennis Geiger (UBS) currently has the highest performing score on PLAY with 6/7 (85.71%) price target fulfillment ratio. His price targets carry an average of $-1.46 (-4.79%) potential downside. Dave & Buster’s Entertainment stock price reaches these price targets on average within 40 days.
aTyr Pharma Shares Phase 3 Results of Efzofitimod in Lung Disease Sarcoidosis
aTyr Pharma has released results from a late-stage study of its drug candidate efzofitimod in people with pulmonary sarcoidosis, a rare lung disease that affects an estimated 200,000 Americans and about 1.2 million people worldwide.
The Phase 3 EFZO-FIT™ study enrolled 268 patients and tested efzofitimod at two dose levels (3.0 mg/kg and 5.0 mg/kg) compared with placebo over 48 weeks. The main goal — reducing the average daily dose of steroids patients needed — was not met. At week 48, patients on the higher dose of efzofitimod reduced steroid use to an average of 2.79 milligrams per day, compared to 3.52 milligrams for those on placebo.
Even though the main target was not achieved, some positive signs were seen. More than half of patients (52.6%) on efzofitimod were able to completely stop using steroids by week 48, compared with 40.2% of those on placebo.
Patients on efzofitimod also reported better lung health scores, with an average improvement of 10.36 points compared with 6.19 points for placebo. About 29.5% of patients on efzofitimod both stopped steroids and saw better lung health scores, compared to 14.4% on placebo. Lung function, measured by breathing tests, stayed stable in both groups.
Analysts Downgrade aTyr Pharma as Price Targets Fall by an Average of 93.8%
- Wells Fargo analyst Derek Archila downgraded from Overweight to Equal-Weight and the price target from $25 to $1.
- RBC Capital analyst Brian Abrahams lowered the rating from Outperform to Sector Perform and the price target from $16 to $1.5.
Which Analyst has the best track record to show on ATYR?
Analyst Joseph Pantginis (HC WAINWRIGHT) currently has the highest performing score on aTyr Pharma. His price targets carry an average of $29.86 (580.93%) potential upside.
Daily Stock Analysts Top Price Moves Snapshot
